SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. [electronic resource]
Producer: 20120102Description: 282-93 p. digitalISSN:- 1365-2125
- Administration, Oral
- Adolescent
- Adult
- Bronchitis -- chemically induced
- CD11b Antigen -- metabolism
- Chemokine CXCL1 -- antagonists & inhibitors
- Cross-Over Studies
- Dose-Response Relationship, Drug
- Double-Blind Method
- Enzyme-Linked Immunosorbent Assay
- Female
- Flow Cytometry
- Humans
- Leukocyte Count
- Male
- Middle Aged
- Neutrophil Activation -- drug effects
- Neutrophils -- immunology
- Ozone -- adverse effects
- Peroxidase -- metabolism
- Phenylurea Compounds -- pharmacokinetics
- Receptors, Interleukin-8B -- antagonists & inhibitors
- Single-Blind Method
- Sputum -- enzymology
- Sulfonamides -- pharmacokinetics
- Young Adult
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.